Post-Market Surveillance Overview
Obligations Do Not End at Approval
Obtaining a NIE is not the end of the regulatory journey — it is the beginning of an ongoing compliance relationship with Kemenkes. Both the foreign manufacturer and the Indonesian LAR have continuing post-market obligations that must be actively managed.
Core PMS Obligations
| Obligation | Who | Frequency |
|---|---|---|
| Adverse event reporting | LAR (on behalf of manufacturer) | As events occur — serious incidents promptly |
| Periodic safety updates | Manufacturer + LAR | As directed by Kemenkes; Class D: regular PSURs |
| Device traceability | LAR | Ongoing; critical for Class C/D |
| Recall readiness and plan | LAR | Documented plan required; activated when needed |
| NIE renewal | LAR | Before 5-year expiry |
| Change notifications | LAR | When device or labeling changes occur |
| CDAKB compliance | LAR | Ongoing; subject to Kemenkes inspection |
| Label compliance | Manufacturer + LAR | Ongoing; Kemenkes conducts market sampling |
Kemenkes Market Sampling
Kemenkes conducts regular market sampling — purchasing products from hospitals and pharmacies across Indonesia and comparing them against the approved label in Regalkes. This serves as a real-world check on label compliance, including:
- Correct NIE number on packaging
- Bahasa Indonesia content present and correct
- Label matches the Regalkes-approved version
- Halal labeling compliance as deadlines pass
Sanctions Regime
Kemenkes operates a tiered sanctions system for non-compliance:
| Level | Sanction | Typical Trigger |
|---|---|---|
| Level 1 | Written warning (surat peringatan) | Minor labeling or documentation non-compliance identified in market sampling |
| Level 2 | NIE suspension | Failure to remedy Level 1 warning; LAR's CDAKB suspended; serious safety concern |
| Level 3 | NIE revocation + mandatory recall | Serious safety risk; persistent non-compliance; fraud; unresolved Level 2 |
A Level 3 revocation with mandatory recall requires the NIE holder to fund and execute the retrieval of all affected products from every hospital and pharmacy in Indonesia — a potentially enormous cost and reputational consequence.
Shared Responsibility
Under the LAR structure, there is a shared responsibility for PMS:
- The LAR is the legally accountable party in Indonesia
- The manufacturer retains technical responsibility for global safety data, FSCA decisions, and product quality
- Effective communication between manufacturer and LAR is essential. A poorly designed or reactive communication protocol is the most common source of PMS failures, particularly when clarification requests, adverse events, or regulatory queries are delayed in reaching the manufacturer's technical team.